October 13, 2017 / 1:08 PM / 2 months ago

BRIEF-Dermira highlights new long-term safety data for glycopyrronium tosylate

Oct 13 (Reuters) - Dermira Inc:

* Dermira highlights new long-term safety data for glycopyrronium tosylate in primary axillary hyperhidrosis at fall clinical dermatology conference

* Dermira Inc - ‍daily treatment with glycopyrronium tosylate in Phase 3, open-label arido trial was generally well-tolerated​

* Dermira - ‍efficacy assessment suggests sweat reduction levels were maintained in patients treated with glycopyrronium tosylate during extended study​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below